This invention comprising in hydroxypropyl starch for preparing empty capsules in alimentary and medical use, and hydroxypropyl starch-based soft capsules. This invention takes water as solvent, mix with propylene epoxide and catalyst for reaction, after washing, drying, hydroxypropyl starch is completed. The MS level of substitution of starch is around 2˜5, gelatinization point between 25˜60° C. After the hydroxypropyl starch is gelatinized by heating in water, a hydroxypropyl starch matrix soft capsule can be prepared. The invention consists in introducing hydroxypropyl by modifying the molecular chain of starch to improve the flexibility and hydrophilicity of starch. Therefore, a hydroxypropyl starch matrix soft capsule capable of preparing a flexible and disintegrating property is provided.

Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

The present invention provides a pharmaceutical composition comprising (R, E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy) phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidinyl-2-yl)-acrylamide or a pharmacologically acceptable salt thereof, which is obtained by mixing the quinoline derivative or a pharmacologically acceptable salt thereof, a wetting agent, a disintegrant, and at least one pharmaceutical excipient; granulating; dynamic drying; and optionally compressing into tablets or filling into capsules after mixing with a lubricant.

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): ##STR00001##
wherein each symbol is as described in the description, or a salt thereof.

The present invention relates to use of gTso thal in manufacturing a medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), and belongs to the technical field of pharmaceutical preparation. Administration of the medicament manufactured by the use of the present invention in combination with MS-275 significantly increases MS-275 to cross the BBB into the brain tissue, and prominently promotes the accumulation of MS-275 therein.

The present invention relates to bioavailable fill compositions containing one or more of a decongestant, an expectorant, an antitussive, an analgesic, and/or an antihistamine; capsules filled with the bioavailable fill compositions; and methods of making same.

A pharmaceutical composition and a health functional food composition for alleviating eye fatigue containing, as active ingredients, compounds, particularly, luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide isolated from a Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo leaf extract have an effect of alleviating eye fatigue by increasing the contents of NO and cGMP associated with relaxation of ciliary smooth muscle cells isolated from rat's eyes and decreasing the content of [Ca.sup.2+]i, and increasing cGMP which is a factor associated with relaxation of the ciliary smooth muscle through an animal experiment. As a result, the luteolin-7-O-diglucuronide and apigenin-7-O-diglucuronide compounds extracted from Perilla frutescens (L.) Britton var. acuta (Thunb.) Kudo may be usefully used as a pharmaceutical composition and a health functional food composition having an eye fatigue alleviating effect as a Korean natural resource.

The present invention relates to a capsule shell with two parts, a cap and a body, the two parts engage telescopically with each other, the capsule shell is used for storing solid substances in powder or granular form and shows a minimized leakage rate of powder when the capsule shell is filled with the solid substances in powder form and is closed.

This disclosure relates to the use of an implantable device to deliver biologically active compounds at a controlled rate for an extended period of time and methods of manufactures thereof. The device is biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.

Provided herein are methods and compositions related to Prevotella bacteria for the reduction of IL-8, IL-6, IL-Iβ, and/C or TNFα expression and/or for the treatment of viral infections.